Pain Managment in Chronic Shoulder Pain
Unknown statusNot applicableNCT06106490
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to evaluate the effect of adding pulsed radiofrequency (PRF) modality to suprascapular nerve injection with ultrasound glenohumeral steroid in chronic shoulder pain patients focusing on both changes in pain and function scores
Study details
- Official title
- Addition of Pulsed Radiofrequency to Suprascapular Nerve Block With Glenohumeral Steroid Injection in Patients With Chronic Shoulder Pain
- Conditions
- Chronic Pain Management
- Interventions
- Other: the effect of adding pulsed radiofrequency (PRF) modality to suprascapular nerve injection with ultrasound glenohumeral steroid in chronic shoulder pain patients
- Sponsor
- Ain Shams University
- Start date
- 2023-11-01
- Primary completion
- 2024-10-30
- Sex
- All
- Age range
- from 21 Years to 60 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adults aged from 21-60 years. * Patients with American Society of Anesthesiologists (ASA) physical status I and II. * Chronic shoulder pain (\>3 months) and will undergo interventional treatment due to inadequate response to conservative treatments. Exclusion Criteria: * Refusal of procedure or participation in the study by patients. * History of shoulder surgery, another intervention history between 3 months before and 1 year after the intervention applied. * Patients with chronic pain syndrome due to other shoulder pathology (fibromyalgia, cervical discopathy, brachial plexus injury). * Uncontrolled diabetes mellitus patients with glycated hemoglobin (HbA1C) levels of more than 7%. * Patients with known history of allergy to the study drugs. * Infection at site of injection. * Cognitive or psychiatric illness that will lead to inability to cooperate, speak, or provide informed consent.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06106490